 This is an open-label phase II, multicenter study. Eligible patients will receive SU011248 in monotherapy 37.5 mg given continuously without interruption. Tumor check-up will be performed every 6-8 weeks. Treatment will be continued until disease progression or unacceptable toxicities according to the patient or the investigator the median for treatment in renal cell study was 8 months. 